Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Moodys
Dow
McKesson
Medtronic

Last Updated: January 26, 2022

Volunteer for clinical trials for METOPROLOL SUCCINATE at ClinicalTrialExchange

DrugPatentWatch Database Preview

METOPROLOL SUCCINATE Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Metoprolol Succinate patents expire, and when can generic versions of Metoprolol Succinate launch?

Metoprolol Succinate is a drug marketed by Actavis Elizabeth, Actavis Labs Fl Inc, Alkem Labs Ltd, Cipla, Dr Reddys Labs Ltd, Hetero Labs Ltd Iii, Mylan Pharms Inc, Nesher Pharms, Novast Labs, Pharmadax Inc, Reddys, Sandoz, Visum Pharm, Wockhardt, Yichang Humanwell, and Zydus Pharms. and is included in twenty NDAs.

The generic ingredient in METOPROLOL SUCCINATE is metoprolol succinate. There are sixty drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the metoprolol succinate profile page.

Drug patent expirations by year for METOPROLOL SUCCINATE
Drug Prices for METOPROLOL SUCCINATE

See drug prices for METOPROLOL SUCCINATE

Drug Sales Revenue Trends for METOPROLOL SUCCINATE

See drug sales revenues for METOPROLOL SUCCINATE

Recent Clinical Trials for METOPROLOL SUCCINATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hackensack Meridian HealthEarly Phase 1
University of Texas Southwestern Medical CenterN/A
Medical University of GdanskPhase 3

See all METOPROLOL SUCCINATE clinical trials

Pharmacology for METOPROLOL SUCCINATE
Anatomical Therapeutic Chemical (ATC) Classes for METOPROLOL SUCCINATE
Paragraph IV (Patent) Challenges for METOPROLOL SUCCINATE
Tradename Dosage Ingredient NDA Submissiondate
TOPROL-XL TABLET, EXTENDED RELEASE;ORAL metoprolol succinate 019962

US Patents and Regulatory Information for METOPROLOL SUCCINATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz METOPROLOL SUCCINATE metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 076969-002 May 18, 2007 DISCN No No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial
Novast Labs METOPROLOL SUCCINATE metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 204106-003 Feb 6, 2018 AB RX No No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial
Wockhardt METOPROLOL SUCCINATE metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 090615-002 Jul 22, 2010 AB RX No No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Boehringer Ingelheim
Harvard Business School
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.